Summary
A prospective randomized double-blind trial comparing the butyrophenone analogue domperidone (D) and the synthetic cannabinoid nabilone (N) in the treatment of cytotoxic-induced emesis was conducted in 38 patients receiving highly emetogenic chemotherapy regimens (70% containing cisplatin). Patients received 20 mg D or 1 mg N the night before chemotherapy and 8-hourly on each chemotherapy day for two consecutive cycles of treatment.
Three of 19 patients randomized to N completed only one cycle because of disease progression (2) or subjectively adverse effects (1). Four of 19 patients completed only one cycle of D because of lack of efficacy (3) or chemotherapy toxicity (1). In all, 32 cycles of N and 33 cycles of D were evaluable for efficacy. The mean number of vomiting episodes in cycle 1 was 4.76 for N and 12.95 for D (P<0.02). The corresponding values for cycle 2 were 4.27 and 7.69 (P>0.10), and for cycles 1 and 2 combined, 4.53 for N and 10.81 for D (P<0.01). Nausea and food intake scores did not differ significantly, although there was a trend towards less nausea and an increased food intake with N. Subjectively adverse effects were more frequent with N and included drowsiness, dizziness, dry mouth, and postural hypotension. N is superior to D for the control of cytotoxic-induced emesis.
Similar content being viewed by others
References
Bakowski MT (1985) Advances in anti-emetic therapy. Cancer Treat Rev 11: 237–256
Coates A, Abraham S, Kaye SB, Sowebutt ST, Frewin C, Fox RM, Tattersall MHN (1983) On the receiving end-patient perception of the side-effects of cancer chemotherapy. Eur J Cancer Clin Oncol 19: 203–208
D'Souza DP, Reyntjens A, Thomas RD (1980) Domperidone in the prevention of nausea and vomiting induced by antineoplastic agents: a three-fold evaluation. Curr Ther Res 27: 384–390
Einhotn L (1978) Nabilone: an effective antiemetic agent in patients receiving cancer chemotherapy. Cancer Treat Rev 9: 55–61
Hamers J (1978) Cytostatic therapy-induced vomiting inhibited by domperidone. A double-blind crossover study. Biomedicine 29: 242–244
Huys J (1978) Cytostatic-associated vomiting effectively inhibited by domperidone (33 812). Cancer Chemother Pharmacol 1: 215–218
Jones SE, Durant JR, Greco FA, Robertone A (1982) A multiinstitutional phase III study of nabilone versus placebo in chemotherapy-induced nausea and vomiting. Cancer Treat Rev 9: 45–48
Kris MG, Tyson LB, Gralla RJ, Clark RA, Allen JC, Reilly LK (1983) Extrapyramidal reactions with high-dose metoclopramide. N Engl J Med 309: 433
Levitt M (1982) Nabilone versus placebo in the treatment of chemotherapy-induced nausea and vomiting. Cancer Treat Rev 9: 49–53
Wada JK, Bogdon DL, Gunnell JC, Hum GJ, Gota CH, Rieth TE (1982) Double-blind, randomised, crossover trial of nabilone versus placebo in cancer chemotherapy. Cancer Treat Rev 9: 39–44
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Pomeroy, M., Fennelly, J.J. & Towers, M. Prospective randomized double-blind trial of nabilone versus domperidone in the treatment of cytotoxic-induced emesis. Cancer Chemother. Pharmacol. 17, 285–288 (1986). https://doi.org/10.1007/BF00256701
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00256701